 |
23 Diseases |  |
162 Trials |
|
162 Trials |  |
4758 News |  |
| «12...56789101112131415...6061» |
- Venclexta (venetoclax) / Roche, AbbVie, Walter and Eliza Hall Institute, Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
REAL WORLD EFFECTIVENESS AND SAFETY OF VENETOCLAX IN COMBINATION WITH OBINUTUZUMAB IN TREATMENT NAIVE CLL PATIENTS () - May 12, 2023 - Abstract #EHA2023EHA_3315;
With this short follow-up, high PFS and OS rates were estimated. Overall, these real-world results confirm the favourable benefit-risk profile of VenO for treatment naive CLL patients as observed in the pivotal CLL14 trial.
- Brukinsa (zanubrutinib) / BeiGene
EFFICACY AND SAFETY OF ONCE DAILY (QD) VS TWICE DAILY (BID) ZANUBRUTINIB FOR PATIENTS WITH VARIOUS B-CELL MALIGNANCIES: A COMPARATIVE SUMMARY OF CLINICAL DATA AND EXPOSURE-RESPONSE ANALYSES () - May 12, 2023 - Abstract #EHA2023EHA_3304;
Comparison of the ORR between QD and BID dosing did not indicate advantage of either regimen. Non-Hodgkin's lymphoma, Tyrosine kinase inhibitor, Pharmacokinetic
- Calquence (acalabrutinib) / AstraZeneca
NAOS STUDY: FIRST INTERIM ANALYSIS OF ACALABRUTINIB USE IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA IN A REAL-LIFE SETTING. () - May 12, 2023 - Abstract #EHA2023EHA_3303;
In this first analysis, most patients received acalabrutinib as first-line therapy. Acalabrutinib was used in patients older than in the published phase III clinical trials, with more frailties (ECOG, creatinine clearance) and cardiovascular risks.
- Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
TREATMENT CHALLENGES OF COEXISTING MYELOID AND LYMPHOID NEOPLASM- A CASE REPORT () - May 12, 2023 - Abstract #EHA2023EHA_3031;
Therefore, in our experience, regular follow-up of patients with myeloid and lymphoid neoplasms coexistence is necessary, primarily because of carrying out treatment of more active malignancy, in accordance to current findings. Because of increased myelosuppressive effect risk if combined treatment is performed, successive therapy is advised.
- Mekinist (trametinib) / Novartis
MEK-KINASE INHIBITOR (TRAMETINIB) AS A TREATMENT OPTION FOR HAIRY CELL LEUKEMIA () - May 12, 2023 - Abstract #EHA2023EHA_2872;
At the same time, the drug is effective in the absence of the MAP2K1 mutation (unlike vemurafenib, which effective only in the presence of the BRAFV600E mutation), and, like vemurafenib, trametinib monotherapy can be effective at a reduced dose (1 mg/day or 1 mg every other day). Kinase inhibitor, Treatment, MEK, Hairy cell leukemia
- Brukinsa (zanubrutinib) / BeiGene, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
MAHOGANY: A PHASE 3 TRIAL OF ZANUBRUTINIB PLUS ANTI-CD20 ANTIBODIES VS LENALIDOMIDE PLUS RITUXIMAB IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR OR MARGINAL ZONE LYMPHOMA () - May 12, 2023 - Abstract #EHA2023EHA_2866;
P3
In R/R follicular lymphoma (FL), ROSEWOOD, a phase 2 randomized study of zanubrutinib plus obinutuzumab vs obinutuzumab, met its primary endpoint of increased overall response rate (ORR) at primary analysis (Zinzani et al. Follicular lymphoma, Non-Hodgkin's lymphoma, Phase III, Marginal zone
- Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
EFFICACY OF OBINUTUZUMAB - BASED REGIMENS IN PATIENTS WITH PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA: A RETROSPECTIVE OBSERVATIONAL SINGLE-CENTER STUDY () - May 12, 2023 - Abstract #EHA2023EHA_2863;
In younger patients with advanced disease, we observed higher rate of complete response and lower probability of need of new anti-lymphoma treatment in O-CHOP group. However, O-CHOP and R-CHOP showed similar efficacy, mostly explained by the fact of short period of follow-up and that half of the patients are still undergoing maintenance treatment.
- IPH6501 / Innate
IPH6501 IS A FIRST-IN-CLASS TETRASPECIFIC ANTIBODY-BASED NATURAL KILLER CELL ENGAGER THERAPEUTIC DEVELOPED FOR THE TREATMENT OF B-CELL NON-HODGKIN'S LYMPHOMAS (Fantasies) - May 12, 2023 - Abstract #EHA2023EHA_2341;
IPH6501 is expected to enter FIH clinical study in 2023. 1.
- REAL-WORLD TREATMENT AND OUTCOMES OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) RECEIVING FIRST-LINE (1L) THERAPY IN THE NOVEL AGENT ERA: AN INTERNATIONAL STUDY (Poster area) - May 12, 2023 - Abstract #EHA2023EHA_2247;
We observed that almost 50% of pts were treated in the front-line setting with anti-CD20 monotherapy or CT/CIT despite availability of targeted agents. The continued use of anti-CD20 monotherapy and CT/CIT is surprising in the era of novel agents.
- Calquence (acalabrutinib) / AstraZeneca
SAFETY AND TREATMENT ADHERENCE WITH ACALABRUTINIB IN VERY OLD (?80Y) AND/OR FRAIL PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) - INTERIM SAFETY ANALYSIS OF THE ONGOING PHASE-II CLL-FRAIL TRIAL (Poster area) - May 12, 2023 - Abstract #EHA2023EHA_2245;
The first interim analysis of this international phase II study evaluating treatment with acalabrutinib in very old and/or frail patients with CLL did not show unexpected safety signals in comparison to prior published data. Comorbidities, Chronic lymphocytic leukemia, Clinical trial, Elderly
- Venclexta (venetoclax) / Roche, AbbVie, Walter and Eliza Hall Institute, Imbruvica (ibrutinib) / AbbVie, J&J
GENETIC ALTERATIONS AND OUTCOMES WITH FIXED-DURATION IBRUTINIB+VENETOCLAX (IBR+VEN): RESULTS FROM THE PHASE 3 GLOW STUDY IN PATIENTS WITH PREVIOUSLY UNTREATED CLL (Poster area) - May 12, 2023 - Abstract #EHA2023EHA_2243;
PFS in pts treated with Ibr+Ven was significantly improved vs Clb+O across most genomic subgroups, including mIGHV and uIGHV. Presence of +12 trended in favor of Ibr+Ven that was NS.
- Calquence (acalabrutinib) / AstraZeneca
CUMULATIVE REVIEW OF HEART FAILURE WITH ACALABRUTINIB IN THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA USING DATA FROM CLINICAL TRIALS AND POST-MARKETING EXPERIENCE (Poster area) - May 12, 2023 - Abstract #EHA2023EHA_2242;
Data from the clinical trial and global safety databases do not suggest that acalabrutinib is associated with a substantially higher risk of CF. Clinical trial, Chronic lymphocytic leukemia, Safety
- Venclexta (venetoclax) / Roche, AbbVie, Walter and Eliza Hall Institute
REAL-WORLD DURATION OF VENETOCLAX TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA AND SMALL LYMPHOCYTIC LYMPHOMA (Poster area) - May 12, 2023 - Abstract #EHA2023EHA_2240;
This study provides evidence that a V-based approach may not be suitable for all patients with CLL/SLL. Future studies should include additional follow-up with a larger sample, reasons for treatment discontinuation, and patient molecular genetic profile.
- Venclexta (venetoclax) / Roche, AbbVie, Walter and Eliza Hall Institute, Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
EARLY-STAGE MEASURABLE RESIDUAL DISEASE DYNAMICS AND IGHV REPERTOIRE RECONSTITUTION DURING VENETOCLAX AND OBINUTUZUMAB TREATMENT IN CHRONIC LYMPHOCYTIC LEUKEMIA (Poster area) - May 12, 2023 - Abstract #EHA2023EHA_2229;
In addition, venetoclax consolidation treatment impaired polyclonal IGHV repertoire reconstitution after induction treatment with O-Ven. Chronic lymphocytic leukemia, Minimal residual disease (MRD), Venetoclax, Obinutuzumab
- Venclexta (venetoclax) / Roche, AbbVie, Walter and Eliza Hall Institute
REAL-WORLD EFFECTIVENESS OF VENETOCLAX-BASED REGIMENS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA IN ISRAEL: UPDATE FROM THE MULTICENTER PROSPECTIVE REVEAL STUDY (Poster area) - May 12, 2023 - Abstract #EHA2023EHA_2228;
In R/R pts,previous exposure to BCRis, del17p/TP53mut, and venetoclax monotherapy are associated with inferior clinical outcomes. Chronic lymphocytic leukemia, Minimal residual disease (MRD), Real world data, MRD
- Venclexta (venetoclax) / Roche, AbbVie, Walter and Eliza Hall Institute, Imbruvica (ibrutinib) / AbbVie, J&J
TRACKING DISEASE PARAMETERS BY MRD, CT AND PET IN FIRST LINE CLL PATIENTS TREATED WITH FIXED DURATION IBRUTINIB-VENETOCLAX; INTERIM ANALYSIS OF THE FIRST 30 PATIENTS IN HOVON 158/NEXT STEP TRIAL. (Poster area) - May 12, 2023 - Abstract #EHA2023EHA_2222;
Detailing responses by CT reveal kinetics of CLL clearance, with faster normalisation of spleen and liver than LN. PET provides additional information on activity of residual CLL sites.
- Venclexta (venetoclax) / Roche, AbbVie, Walter and Eliza Hall Institute, Zydelig (idelalisib) / Gilead, Imbruvica (ibrutinib) / AbbVie, J&J
GENETIC MARKERS AND OUTCOME OF CLL PATIENTS IN COMBINED TIME-LIMITED TREATMENT WITH ANTI-CD20 ANTIBODY + IBRUTINIB, IDELALISIB OR VENETOCLAX IN THE GCLLSG CLL2-BAG, -BCG, -BIG AND -BIO PHASE-II TRIALS (Poster area) - May 12, 2023 - Abstract #EHA2023EHA_2221;
PET provides additional information on activity of residual CLL sites. Four phase-2 trials of the German CLL Study Group evaluated time-limited combination regimens in treatment-na
- Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Calquence (acalabrutinib) / AstraZeneca
TIME-LIMITED TREATMENT WITH ACALABRUTINIB PLUS OBINUTUZUMAB IN TREATMENT-NA (Poster area) - May 12, 2023 - Abstract #EHA2023EHA_2219;
P2
Longer treatment and follow-up are warranted to determine the durability of responses after therapy discontinuation. Figure: Bone marrow MRD levels during treatment with acalabrutinib and obinutuzumab.
- Venclexta (venetoclax) / Roche, AbbVie, Walter and Eliza Hall Institute, etrumadenant (AB928) / Arcus Biosci, Otsuka, Gilead, Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
T-CELL DYSFUNCTION BY PSEUDOHYPOXIA AND AUTOCRINE PURINERGIC SIGNALING IN CHRONIC LYMPHOCYTIC LEUKEMIA (Poster area) - May 12, 2023 - Abstract #EHA2023EHA_2195;
This novel mechanistic insight suggests that modulation of hypoxia and the purinergic pathway might contribute to therapeutic restoration of T-cell function. B cell chronic lymphocytic leukemia, Cancer immunotherapy
- Evusheld (cilgavimab/tixagevimab) / AstraZeneca
TIXAGEVIMAB-CILGAVIMAB THERAPY IN THE PREVENTION OF SARS-COV2 INFECTION IN NON-HODGKIN-B LYMPHOMAS AND HODGKIN LYMPHOMAS UNDER TREATMENT: OUR EXPERIENCE (Poster area) - May 12, 2023 - Abstract #EHA2023EHA_1942;
F rom our experience, prevention therapy does not seem to have changed the incidence and prognosis of theSARS-COV2 infection, certainly variables that seem to influence are age (75 vs 55 years) and the total IgG value (patients with severe symptoms had a median IgG of 415 mg/dl vs 817 mg/dl in patients with mildly symptomatic COVID), further in patients with mild symptoms the COVID infection did not interfere with the continuation of the specific treatment, we do not know if in these cases it could to helping the preventive therapy. A larger cohort of patients is needed to consolidate or confirm the data of our observation.
- Venclexta (venetoclax) / Roche, AbbVie, Walter and Eliza Hall Institute, Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Calquence (acalabrutinib) / AstraZeneca
SERIAL SINGLE-CELL PROFILING OF MANTLE CELL LYMPHOMA REVEALS FUNCTIONAL AND MOLECULAR CORRELATES OF RESISTANCE TO BTK INHIBITOR-INCLUSIVE TRIPLET THERAPY (Poster area) - May 12, 2023 - Abstract #EHA2023EHA_1548;
P1/2
Our long-term goal is to leverage biophysical properties toresolve functionally resistant cellular subclones in which to focus single-cell multi-omics to nominate candidate targets for precision therapeutic strategies. Clinical trial, Bruton's tyrosine kinase inhibitor (BTKi), Mantle cell lymphoma, Drug resistance
- Columvi (glofitamab) / Roche
GLOFITAMAB MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) LARGE B-CELL LYMPHOMA (LBCL): EXTENDED FOLLOW-UP AND LANDMARK ANALYSES FROM A PIVOTAL PHASE II STUDY (Poster area) - May 12, 2023 - Abstract #EHA2023EHA_1448;
P1/2
These data support the potential for favorable long-term outcomes with fixed-duration glofitamab for R/R LBCL. Updated analyses, including a larger population with a median CR follow up of approximately 20 months post-EOT, will be presented.Figure: Duration of complete response in patients with R/R LBCL who received glofitamab monotherapy LBCL, large B-cell lymphoma; R/R, relapsed/refractory
- Columvi (glofitamab) / Roche, poseltinib (HM71224) / Hanmi
PHASE II STUDY OF GLOFITAMAB, POSELTINIB AND LENALIDOMIDE IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE B CELL LYMPHOMAS (Poster area) - May 12, 2023 - Abstract #EHA2023EHA_1407;
P2
Glofitamab, poseltinib and lenalidomide (GPL) is promising combination for thetreatment of R/R DLBCL. (Table) Refractory, DLBCL, Bispecific
- bendamustine / Generic mfg.
CLINICAL IMPLICATIONS OF T CELL SUBSET COMPOSITION DURING MAINTENANCE THERAPY AFTER FIRST-LINE IMMUNOCHEMOTHERAPY CONTAINING BENDAMUSTINE IN PATIENTS WITH FOLLICULAR LYMPHOMA (Poster area) - May 12, 2023 - Abstract #EHA2023EHA_1359;
Background: First-line immunochemotherapy of Follicular lymphoma (FL) combining anti-CD20 antibodies Rituximab or Obinutuzumab with Bendamustine (R/O-B) followed by maintenance therapy results in high rates of response and long progression-free survival. FL pts undergoing first-line therapy with R/O-B experienced a prolonged and deep CD4+T and lymphopenia, in particular of the na
- Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
OBINUTUZUMAB INDUCTION AND MAINTENANCE IN PATIENTS WITH RELAPSED/REFRACTORY WALDENSTR (Poster area) - May 12, 2023 - Abstract #EHA2023EHA_1354;
P2
FL pts undergoing first-line therapy with R/O-B experienced a prolonged and deep CD4+T and lymphopenia, in particular of the na Background: Chemoimmunotherapy based on rituximab remains the cornerstone of treating symptomatic patients with Waldenstr
- Brukinsa (zanubrutinib) / BeiGene, Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
ZANUBRUTINIB PLUS OBINUTUZUMAB VERSUS OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: UPDATED ANALYSIS OF THE ROSEWOOD STUDY (Poster area) - May 12, 2023 - Abstract #EHA2023EHA_1347;
P2
Zanubrutinib plus obinutuzumab demonstrated meaningful activity and a manageable safety profile in patientswith heavily pretreated R/R FL, representing a potential novel therapy. Non-Hodgkin's lymphoma, Follicular lymphoma, Phase II
- Venclexta (venetoclax) / Roche, AbbVie, Walter and Eliza Hall Institute, Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Imbruvica (ibrutinib) / AbbVie, J&J
LONG TERM FOLLOW-UP OF UNTREATED/RELAPSING MCL PATIENTS WITH THE IBRUTINIB, OBINUTUZUMAB, AND VENETOCLAX COMBINATION. (Poster area) - May 12, 2023 - Abstract #EHA2023EHA_1341;
P1/2, P2
The anti-CD20+Ibrutinib vs anti-CD20+Ibrutinib+Venetoclax combinations are currently under investigation in OASIS-II trial (NCT04802590) for untreated patients with MCL. Venetoclax, ibrutinib, Targeted therapy, Mantle cell lymphoma
- Venclexta (venetoclax) / Roche, AbbVie, Walter and Eliza Hall Institute, Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Tecentriq (atezolizumab) / Roche
EFFICACY AND SAFETY RESULTS OF MOLTO, A MULTICENTER, OPEN LABEL, PHASE II CLINICAL TRIAL EVALUATING VENETOCLAX, ATEZOLIZUMAB AND OBINUTUZUMAB COMBINATION IN RICHTER SYNDROME (Panorama 1) - May 12, 2023 - Abstract #EHA2023EHA_895;
P2
This regimen led to durable remissions, longer than 2 years in one third of responders. B cell chronic lymphocytic leukemia, Venetoclax, Obinutuzumab, Transformation
- Venclexta (venetoclax) / Roche, AbbVie, Walter and Eliza Hall Institute, Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
VENETOCLAX-OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 6-YEAR RESULTS OF THE RANDOMIZED CLL14 STUDY (Panorama 1) - May 12, 2023 - Abstract #EHA2023EHA_893;
These data confirm a long-term PFS benefit of fixed-duration Ven-Obi treatment compared to Clb-Obi, including patients with high-risk CLL.Fiveyears after completing Ven-Obi, over half of patients remained in remission,and over 60% had not required second-linetreatment.The 1-year Ven-Obi regimen is an effectivefixed-duration option for patients with CLL and coexisting conditions. Keywords: Obinutuzumab, Venetoclax, B-CLL, Chronic lymphocytic leukemia
- |||| Clinical: 👏👏👏Promising results from the GAIA CLL13 trial shedding light on time-limited therapy in young fit #CLL patients Venetoclax–Obinutuzumab and Venetoclax–Obinutuzumab–Ibrutinib regimens exceed CIT while Rituximab-Venetoclax falls behind. (Twitter) - May 11, 2023
- |||| Venclexta (venetoclax) / Roche, AbbVie, Walter and Eliza Hall Institute, Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Imbruvica (ibrutinib) / AbbVie, J&J
Monotherapy: Thank you @jeff_sharman. One of the next trials, #CLL17, which has finished recruitment, will hopefully give some answers, as it compares Venetoclax (Ven)-Ibrutinib to Ven-Obinutuzumab and continued Ibrutinib monotherapy. (Twitter) - May 11, 2023
- |||| Venclexta (venetoclax) / Roche, AbbVie, Walter and Eliza Hall Institute, Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Imbruvica (ibrutinib) / AbbVie, J&J
Clinical: Venetoclax–obinutuzumab +/- ibrutinib is superior to chemoimmunotherapy as first-line treatment in fit patients with CLL-GAIA–CLL13 https://t.co/VdiT4whyTZ (Twitter) - May 10, 2023
- | Enrollment change, Combination therapy: Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma (clinicaltrials.gov) - May 9, 2023
P1, N=55, Recruiting, Sponsor: National Cancer Institute (NCI)
Keywords: Obinutuzumab, Venetoclax, B-CLL, Chronic lymphocytic leukemia N=32 --> 55
- | Columvi (glofitamab) / Roche, Lunsumio (mosunetuzumab) / Roche, Biogen
Trial primary completion date, CAR T-Cell Therapy: CAR-T Followed by Bispecific Antibodies (clinicaltrials.gov) - May 8, 2023
P2, N=42, Recruiting, Sponsor: Abramson Cancer Center at Penn Medicine
N=32 --> 55 Trial primary completion date: Dec 2023 --> Dec 2024
- ||||| Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Rituxan (rituximab) / Roche, Epkinly (epcoritamab-bysp) / Genmab, AbbVie
New P2 trial: REFRACT: Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy (clinicaltrials.gov) - May 8, 2023
P2, N=284, Not yet recruiting, Sponsor: University of Birmingham
- || Venclexta (venetoclax) / Roche, AbbVie, Brukinsa (zanubrutinib) / BeiGene, Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
Trial completion date, Trial primary completion date: Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL) (clinicaltrials.gov) - May 6, 2023
P2, N=127, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Trial primary completion date: Dec 2023 --> Dec 2024 Trial completion date: Feb 2023 --> Feb 2024 | Trial primary completion date: Feb 2023 --> Feb 2024
- | Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
New trial: Obinutuzumab in the Management of Idiopathic Membranous Nephropathy (clinicaltrials.gov) - May 6, 2023
P=N/A, N=30, Not yet recruiting, Sponsor: Qianfoshan Hospital
- | Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
New trial, Combination therapy, Real-world evidence, Real-world: Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Follicular Lymphoma in Real World Study (clinicaltrials.gov) - May 6, 2023
P=N/A, N=50, Recruiting, Sponsor: Institute of Hematology & Blood Diseases Hospital
- | Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
New P2 trial, Combination therapy: Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Marginal Zone Lymphoma (clinicaltrials.gov) - May 6, 2023
P2, N=59, Recruiting, Sponsor: Institute of Hematology & Blood Diseases Hospital
- || Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
Review, Journal: Obinutuzumab-induced acute thrombocytopenia: Report of two cases and review of literature. (Pubmed Central) - May 5, 2023
The first case is a 74 year- old woman who was treated with obinutuzumab-Cyclophosphamide, Vincristine, Prednisone (CVP) for a previously untreated follicular lymphoma...The second case is a 44 year- old woman who was treated with obinutuzumab as a pre-treatment dose (day-8) before glofitamab infusion as a 4th line therapy for mantle cell lymphoma...OIAT is a rare but life-threatening complication. Physicians should be aware of this adverse event to optimally detect and treat this complication.
- Venclexta (venetoclax) / Roche, AbbVie, Walter and Eliza Hall Institute, Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Calquence (acalabrutinib) / AstraZeneca
A Phase 3 Trial of Acalabrutinib, Obinutuzumab and Venetoclax Compared to Obinutuzumab and Venetoclax in Patients with High Risk Chronic Lymphocytic Leukemia () - May 4, 2023 - Abstract #ICML2023ICML_979;
- Venclexta (venetoclax) / Roche, AbbVie, Walter and Eliza Hall Institute, Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Imbruvica (ibrutinib) / AbbVie, J&J
Venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide (ViPOR) in relapsed/refractory (R/R) and treatment-na () - May 4, 2023 - Abstract #ICML2023ICML_718;
- Venclexta (venetoclax) / Roche, AbbVie, Walter and Eliza Hall Institute, Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Imbruvica (ibrutinib) / AbbVie, J&J
Long term follow-up of untreated/relapsing MCL patients with the Ibrutinib, obinutuzumab, and venetoclax combination. () - May 4, 2023 - Abstract #ICML2023ICML_633;
- Brukinsa (zanubrutinib) / BeiGene, Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
Targeting BTK across B-Cell Malignancies (Auditorium West Campus USI) - May 4, 2023 - Abstract #ICML2023ICML_408;
Professor Zinzani will present the status and current treatment status in FL including emerging data from the randomized Phase 2 ROSEWOOD trial in patients with relapsed or refractory FL (zanubrutinib in combination with obinutuzumab vs. obinutuzumab monotherapy). Both chairpersons will then lead the panel discussion with the full faculty to discuss the key criteria, supported by additional patient cases, for selecting a BTKi versus other treatment options for CLL, FL, MZL and WM, especially for difficult-to-treat patients.
- Venclexta (venetoclax) / Roche, AbbVie, Walter and Eliza Hall Institute, Brukinsa (zanubrutinib) / BeiGene, Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
Long-term follow-up of multicenter phase II trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in previously untreated patients with CLL/SLL (Room B) - May 4, 2023 - Abstract #ICML2023ICML_299;
- Brukinsa (zanubrutinib) / BeiGene, Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
Zanubrutinib plus obinutuzumab versus obinutuzumab in patients with relapsed/refractory follicular lymphoma: Updated analysis of the ROSEWOOD study (Room A) - May 4, 2023 - Abstract #ICML2023ICML_269;
- Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
High rate of metabolic complete response after low dose radiotherapy and Obinutuzumab in early stage follicular lymphoma: Initial results of the GAZAI study (GLA 2018-3) (Auditorium) - May 4, 2023 - Abstract #ICML2023ICML_184;
- Venclexta (venetoclax) / Roche, AbbVie, Walter and Eliza Hall Institute, Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Tecentriq (atezolizumab) / Roche
Efficacy and safety of MOLTO, a multicenter, open label, phase II clinical trial evaluating venetoclax, atezolizumab and obinutuzumab combination in Richter Syndrome (Room A) - May 4, 2023 - Abstract #ICML2023ICML_134;
- Venclexta (venetoclax) / Roche, AbbVie, Walter and Eliza Hall Institute, Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
Venetoclax-Obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized CLL14 study (Room A) - May 4, 2023 - Abstract #ICML2023ICML_132;
- MIL62 / Beijing Mabworks Biotech
THE TYPE ? ANTI-CD20 MONOCLONAL ANTIBODY MIL62 OR CYCLOSPORINE (Focussed Oral Room 2) - May 4, 2023 - Abstract #ERAEDTA2023ERA_EDTA_1715;
P1/2
MIL62 had a manageable safety profile. This phase Ib/II preliminary data warrant further phase III clinical trials of MIL62 in pMN.